(0.06%) 5 251.40 points
(0.06%) 39 782 points
(-0.12%) 16 379 points
(1.62%) $82.67
(0.70%) $1.730
(1.00%) $2 234.90
(0.55%) $24.89
(1.34%) $921.85
(0.27%) $0.926
(0.68%) $10.84
(0.00%) $0.791
(0.17%) $92.60
Live Chart Being Loaded With Signals
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease...
Stats | |
---|---|
Today's Volume | 228 434 |
Average Volume | 414 645 |
Market Cap | 1 069.53B |
EPS | KRW-279.60 ( 2024-03-18 ) |
Next earnings date | ( KRW0 ) 2024-05-09 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW71.69 (0.25%) |
Volume Correlation
Oscotec Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oscotec Inc. Correlation - Currency/Commodity
Oscotec Inc. Financials
Annual | 2023 |
Revenue: | KRW4.95B |
Gross Profit: | KRW1.23B (24.85 %) |
EPS: | KRW-634.86 |
Q4 | 2023 |
Revenue: | KRW305.77M |
Gross Profit: | KRW-772.00M (-252.47 %) |
EPS: | KRW-279.60 |
Q3 | 2023 |
Revenue: | KRW1.70B |
Gross Profit: | KRW748.98M (44.16 %) |
EPS: | KRW-118.18 |
Q2 | 2023 |
Revenue: | KRW1.80B |
Gross Profit: | KRW876.36M (48.68 %) |
EPS: | KRW-100.82 |
Financial Reports:
No articles found.
Oscotec Inc.
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators